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Abstract
Background: Aimed to facilitate candidate biomarkers selection and improve network-based multi-target therapy,
we perform comparative proteomics research on muscle-invasive bladder transitional cell carcinoma. Laser capture
microdissection was used to harvest purified muscle-invasive bladder cancer cells and normal urothelial cells from
4 paired samples. Two-dimensional liquid chromatography tandem mass spectrometry was used to identify the
proteome expression profile. The differential proteins were further analyzed using bioinformatics tools and
compared with the published literature.
Results: A total of 885/890 proteins commonly appeared in 4 paired samples. 295/337 of the 488/493 proteins that
specific expressed in tumor/normal cells own gene ontology (GO) cellular component annotation. Compared with
the entire list of the international protein index (IPI), there are 42/45 GO terms exhibited as enriched and 9/5
exhibited as depleted, respectively. Several pathways exhibit significantly changes between cancer and normal
cells, mainly including spliceosome, endocytosis, oxidative phosphorylation, etc. Finally, descriptive statistics show
that the PI Distribution of candidate biomarkers have certain regularity.
Conclusions: The present study identified the proteome expression profile of muscle-invasive bladder cancer cells
and normal urothelial cells, providing information for subcellular pattern research of cancer and offer candidate
proteins for biomarker panel and network-based multi-target therapy.
Background
Despite elaborate characterization of the risk factors,
muscle-invasive bladder transitional cell carcinoma
(BTCC) is still a major epidemiological problem whose
incidence continues to rise each year [1]. The standard
therapeutic methods of muscle-invasive BTCC are radi-
cal cystectomy (RC) followed postoperative care.
Though there are much progress in surgical techniques
and perioperative chemoradiation, the 5-year disease
specific survival after RC remains 50-60% [2]. At pre-
sent, the detailed mechanism for the carcinogenesis and
development of invasive bladder carcinoma remains to
be elucidated.
Though there were several proteomics research on
muscle-invasive BTCC and make certain progress, the
achievement of these researches were confined by the
limited proteins identified from cancer tissue [3-5].
Nowadays, sophisticated proteomic, computational, and
statistical tools offer us increased possibility of assimilat-
ing existing data to discover cancer biology and develop
effective biomarkers for diagnosis and targeted therapy
[6]. Meanwhile, with these technologies, some new con-
cepts such as biomarker panel, subcellular proteomics
study, and network-based multi-target therapy has been
widely accepted [7-9].
Out of the above background, we perform shotgun
strategy namely two dimensional liquid chromatography
in conjunction with tandem mass spectrometry (2D-LC-
MS/MS) for the direct analysis of complex mixtures as
the initial step of our proteomics approach to under-
standing biology of invasive bladder cancer and to dis-
cover biomarkers. In order to exclude the interference
of stromal elements and adjoining cells, purified cancer
cells were obtained by laser capture microdissection.
Based on the expression profile of purified cancer cells,
* Correspondence: niuhaitao1976@gmail.com
† Contributed equally
1Department of Urology, The Affiliated Hospital of Medical College Qingdao
University, Qingdao, China
Full list of author information is available at the end of the article
Niu et al. Cancer Cell International 2011, 11:17
http://www.cancerci.com/content/11/1/17
© 2011 Niu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.gene ontology (GO) cellular component analysis was
performed and the global feature of the expression pro-
file as well as biomarker panel discovery was discussed.
Aimed to achieve a systematical description of pathway
changes and facilitate the network-based target therapy,
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database was retrieved.
Methods
Patients and tissue samples
A total of 4 paired muscle-invasive BTCC and normal
urothelium samples (confirmed by two individual patho-
logical diagnoses) were obtained from patients treated at
the The Affiliated Hospital of Medical College Qingdao
University immediately after radical cystectomy due to
primary invasive bladder cancer. No patient had distant
metastatic disease at cystectomy and no patient pre-
sented with carcinoma in situ. Pathologic staging and
grading were performed according to the 2002 TNM
classification system and World Health Organization
criteria, respectively. The tumor and the adjacent micro-
scopically normal urothelium (away from 5 cm) samples
were rinsed in sterile PBS and snap frozen in liquid
nitrogen within 30 min of removal. Table 1 lists the
major clinical and pathological features of the 4 patients.
The research protocol was approved by the Institutional
Review Board and informed consent was obtained from
patients.
Laser capture microdissection
Eight-micrometer sections of freshly prepared tissues
were stained with hematoxylin and eosin (H&E) to
guide microdissection. The sections were air-dried and
microdissected with a Leica AS LMD Laser Capture
Microdissection System. Approximately 500, 000 shoots
of tumor and normal urothelial cells from each speci-
men were microdissected and stored on microdissection
caps at -80°C until lysed. Each cell population was
determined to be 95% homogeneous by microscopic
visualization of the captured cells. To avoid the degrada-
tion of protein, we capture the cells within 120 min
each cap. Figure 1 shows a representative LCM of the
sample. Laser capture microdissected cells were dis-
solved in lysis buffer (95 mM urea, 4% CHAPS, 40 mM
Tris, 65 mM DTT). Samples were solubilized via
sonication using 20 s bursts, followed by ice cooling (20
s), in a process that was repeated 5 times. After that,
samples were centrifuged for 45 min at 15 000 rpm to
remove DNA, RNA, and any particulate materials. The
protein concentrations of samples were measured by
Bio-Rad protein assay kit. All samples were stored at
-80°C until use.
Digestion of protein mixture for analysis
Samples prepared by LCM technology were deposited in
precipitation solution (50% acetone/50% ethanol/0.1%
acetic acid, sample volume: precipitation solution
volume = 1:5) for at least 12 h at -20°C. The pellets
were washed by 100% acetonea n d7 0 %e t h a n o l ,t h e n
redissolved in 6 mM guanidine-HCl/100 mM Tris (pH
8.3), and the concentrations were measured by Bio-Rad
protein assay kit. Next, 250 μg of soluble proteins were
reduced with DTT (final concentration 20 mM) and
subsequently alkylated with IAA (final concentration 40
mM). After desalting and removal of hematoxylin and
eosin by ultrafiltration with Microcon-10, the protein
mixture was incubated with trypsin (trypsin: protein
mixture = 1:30 w/w; Promega) at 37°C for 20 h.
2D-LC-MS/MS
All the two-dimensional high-performance LC separa-
tions were performed on a ProteomeX work station
equipped with two capillary LC pumps. The flow rate of
both salt and analytical pumps was at 120 μl/min and
was about 1.5 μl/min after split. Nine different salt con-
centration ranges from 0, 25, 50, 75, 100, 150, 200, 400,
and 800 mM ammonium chloride were used for step
gradient. The mobile phases used for reverse phase
w e r e :A ,0 . 1 %f o r m i ca c i di nw a t e r ,p H3 . 0 ;B ,0 . 1 %f o r -
mic acid in acetonitrile. Finnigan LTQ was used for
peptide detection. The positive ion mode was employed
and the spray voltage was set at 3.0 kV. The spray tem-
perature was set at 170°C for peptides. Collision energy
was set at 35%. After acquisition of full-scan mass spec-
tra, ten MS/MS scans were acquired for the next ten
most intense ions using dynamic exclusion. Peptides
and proteins were identified using Sequest software,
which uses the MS and MS/MS spectra of peptide ions
to search against the publicly available IPI (International
Protein Index) database. The protein identification cri-
t e r i at h a tw eu s e dw e r eb a s e do nD e l t aC N( ≥ 0.1) and
Xcorr (one charge ≥ 1.9, two charges ≥ 2.2, three
charges ≥ 3.75).
GO and GO enrichment/depletion analysis
To take an overview of our proteomics analysis of inva-
sive bladder cancer, we categorized the normal/cancer
cells specific proteins as to GO assignments http://www.
geneontology.org and GOfact software was used for the
Table 1 The major clinical and pathological features of
the clinical samples
Patient Age Gender Stage Grade Multifocality Configuration
No.1 56 male T2 G3 yes Solid
No.2 48 male T2 G3 yes Solid
No.3 52 male T2 G2 yes Solid
No.4 61 female T2 G3 yes Solid
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depletion analysis, a test dataset (which is our identified
proteins) and a reference set of GO annotation for the
complete human proteome were in need. As per instruc-
tions on the GOfact webpage, the custom GO annotation
for the reference set (of whole IPI human dataset) was
created by extracting the GO annotations available for
Human IPI IDs from EBI GOA Human 56.0 release. The
analysis was done using fisher’s exact test; the GO terms
with P <0 . 0 5o rP < 0.01 were selected as enriched/
depleted or significantly enriched/depleted.
Pathway analysis
ArrayTrack software was used for pathway analysis.
ArrayTrack offers a simple query interface to retrieve
information about human protein expression profile, and
provides direct connections to related biological path-
ways available from Kyoto Encyclopedia of Genes and
Genomes (KEGG). As to the ArrayTrack manual, the IPI
names of the differentially expressed proteins were con-
verted to SWISS-PROT names by ID convert tool prior
to pathway analysis and then go to Pathway Search panel
[11]. For statistical analysis, a P value for pathway enrich-
ment was obtained using the fisher’se x a c tt e s ta n dP <
0.05 was considered statistically significant.
Descriptive statistics on candidate biomarkers
The proteins that located in KEGG pathways by Array-
Track were defined as potential biomarkers and the
basic physico-chemical property of these proteins were
further discussed. Skewness and kurtosis were used to
test the distribution of the data. Mean values ± standard
deviation was used to describe the central tendency and
spread of normal distribution data. Interquartile-range
(IQR) was used to give the basic characteristic of the
variability skewness distribution data. All analysis was
performed with SPSS
®,v e r s i o n1 6 . 0a n dP <0 . 0 5w a s
considered statistically significant.
Results
Identification of the proteins
From the 4 paired specimens we identified 990/983; 976/
1032; 996/1058; and 1036/1011 proteins, respectively. This
study mainly aimed to obtain global description of the bio-
logical characteristic of invasive bladder cancer. Therefore,
we only analyzed the 885/890 proteins that commonly
appeared in 4 paired specimens. There were 981 differen-
tially expressed proteins between tumor and normal tissue.
Among them, 488 proteins specifically expressed in cancer
cells and 493 specifically expressed in normal cells. The
smallest and largest molecular weight (MW) values
observed in differentially expressed proteins were 7.34 and
1153.21 kDa, and the proteins were distributed across a
wide isoelectric point (PI) range (3.67-12.14).
GO and GO enrichment/depletion analysis
Of all the 488/493 proteins that were specifically
expressed in tumor/normal cells, 295/337 with cellular
component annotation. Compared with the entire list of
the IPI (IPI Human, versions 3.13; 57050 protein
sequences), there were 42/45 GO terms exhibited as
enriched and 9/5 exhibited as depleted, respectively. Fig-
ure 2 shows enrichment/depletion analysis of cellular
component. 27/24 proteins belong to the term of cytos-
keleton, 23/40 belong to the term of mitochondrion, 11/
24 proteins belong to the term of endoplasmic reticu-
lum in tumor/normal tissue, respectively (Table 2).
Significant pathways and identification of potential
biomarkers
After ID conversion, 745 of the 981 differential proteins
with SWISS-PROT names and were analyzed by Array-
Track. After analysis, 360 proteins were located at the
well-known biological KEGG pathways and defined as
potential biomarkers. The significantly altered pathways
mainly include spliceosome, endocytosis, oxidative phos-
phorylation, etc. These pathways may take decisive role
in the multistep tumorigenesis and development of inva-
sive bladder cancer. Table 3 lists the major altered
pathways.
Descriptive statistics on candidate biomarkers
ArrayTrack defined a total of 360 proteins as potential
biomarkers. Figure 3 and Figure 4 show the distribution
of PI and MW about the potential biomarkers as well as
the skewness distribution of the data. When the data is
Figure 1 Harvest the tumor cancer cells by LCM. (A) Before LCM; (B) after LCM; Harvest the normal urothelium by LCM. (C) Before LCM; (D)
after LCM
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Page 3 of 8subdivided by PI equal 9 and MW equal 100 kDa, the
IQR is 1.97 for PI ≤ 9 and 1.14 for PI > 9, 33.28 for
MW ≤ 100 and 130.84 for MW > 100, respectively.
After further division and analyses, the data that PI ≤ 8
and 8 < PI ≤ 10 include 242, 94 proteins respectively
have normal distribution and the mean ± SD is 5.98 ±
0.86 and 8.94 ± 0.51. Though the data that MW ≤ 70
looks like normal distribution, the pseudomorphism was
see through by descriptive statistics with a P value >
0.05.
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Figure 2 Enriched/depleted GO cellular component terms for the set of tumor/normal cells specific proteins.P u r p l e / r e di n d i c a t e s
enriched terms in normal/cancer cells; light green/dark green indicate depleted terms in normal/cancer tissue. Underline indicates significantly
enriched/depleted terms.
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LCM technology can provide homogeneous sub-cell
populations and minimising confounding variables,
then we perform LCM prior to comparative proteo-
mics analysis of muscle-invasive BTCC. After peptide
mixture detection by 2D-LC-MS/MS, there were 885/
890 proteins that commonly appeared in 4 paired
tumor/normal specimens. Several biomarker candidates
for cancer research in this profile have been previously
reported. A critical functional consequence for obser-
vations connecting HNRNPA1 upregulation with cell
proliferation, transformation has been demonstrated in
a wide variety of cancers [12]. The activation of PLCB1
is an early and common response to stimulation of G
protein-coupled receptors by these neuroendocrine
growth factors and has been used for diagnostic and
therapeutic target in lung cancer and multiple blood
diseases [13]. Other examples are CYCS, COX5B, etc
[14,15].
Cancer is now appreciated as a disease involving dys-
function of multiple subcellular pattern governing fun-
damental cell processes [16]. GO analysis on enlarged
proteome coverage offer the predominance that select
specific subcellular pattern to yield relatively simpler
dataset for further research instead of whole-cell or
whole-tissue proteome [17]. Compared with all human
proteins deposited on IPI, the GO enrichment/depletion
of the subcellular pattern mean the proteins in these
categories are over/under presented in this profile and
reflect the biologically specific categories of these data.
By this way, shotgun strategy can understand carcino-
genesis by subcellular level even without consideration
of differentially abundant. As shown in Figure 2, our
observation indicated that the global over/under repre-
sented terms in subcellular pattern of invasive bladder
cancer and normal urothelium was quite consistent.
Besides the global consistence, the proteins belonging to
each pattern were completely different. The different
Table 2 Proteins belong to cytoskeleton, mitochondrion, endoplasmic reticulum by GO enriched/depletion analysis
GO term SWISS-PROT name
cancer Normal
Cytoskeleton RFA1, TMOD2, ACTH, DAG1, ACTZ, SRC8, FAK2, FSCN1, MYO3A,
CTNA1, TBCA, TLN2, STOM, HINT1, NUCB1, SPR2E, DLG4, PTN14,
ALDOC, LSP1, LIMA1, NHRF1, ABI1, CLIC4, CCDC6, NEBU, Q05331
ARAP3, JAK2, SSH1, MICA2, TPM3, MACF1, MYCB2, DPYL2, CK5P2,
ABL2, STML2, FHOD3, SYNPO, COF2, NUDC, D9YZV3, TWF2,
B4DQR8, UTRO, ANK2, GDIR2, TMOD3, LASP1, Q9Y427
Mitochondrion GSHR, C1QBP, COX5B, ATPD, NDUS6, THIL, SSBP, CC90A, ATP5I,
CH10, QCR7, QCR1, ADT2, ALDH2, IPYR2, PEDF, ACSS3, TIM8B,
CLIC4, B2R608, ALDOC, Q5VTS5, GSHPx
B4DJA0, ETFA, IDHP, CATD, ECH1, PRDX4, DLDH, DHE3, COX2,
HCD2, SODM, CH3L2, ECHM, PUR2, EFTU, PHB2, NDUA3, CY1,
MCL1, S2533, AL1B1, ADHX, S10AA, C1TC, CY24B, SODC, CATB,
QCR2, RPOM, STML2, ODO2, NDUA5, CYC, NEUL, HSP72, ATPO,
PP1G, DECR, SYVC, AIFM1
Endoplasmic
reticulum
RTN-1C, CAV1, EST1, EGFR, PDIA5, RCN3, RAB14, OST48, CNBP,
ABI1, ACOC
HYOU1, SAR1B, FKBP2, SPTC1, PRAF3 HYEP, EXTL3, SC23A, HCD2,
HNRPQ, LGAT1, THY1, TMED9, AN32A, LMAN1, ERD21, SERPH,
DNJC1, CISD2, TXND5, APEX1, SC61B, SPCS3, CP19A
Table 3 Major altered pathways
Pathway SWISS-PROT name
Spliceosome ACIN1, BCAS2, CRNKL1, EIF4A3, HNRNPA1, HNRNPA3, HNRNPM, HSPA2, LSM3, PRPF8, PUF60, SF3B1, SFRS13A, SFRS3,
SFRS6, SFRS9, SNRPB, SNRPD2, SNRPD3, SNRPF, SNRPG, TRA2A, TRA2B
Huntington’s disease ATP5D, ATP5O, CLTA, CLTC, CLTCL1, COX2, COX5B, CYC1, CYCS, DLG4, DNAH2, EP300, NDUFA3, NDUFA5, NDUFS6,
PLCB1, POLR2D, RCOR1, SLC25A5, SOD1, SOD2, UQCRB, UQCRC1, UQCRC2, VDAC2
Alzheimer’s disease ADAM10, ATP2A2, ATP2A3, ATP5D, ATP5O, CAPN2, COX2, COX5B, CYC1, CYCS, GRIN2C, HSD17B10, LRP1, NDUFA3,
NDUFA5, NDUFS6, PLCB1, PPP3R1, TNF, UQCRB, UQCRC1, UQCRC2
Endocytosis ARAP3, CLTA, CLTC, CLTCL1, EGFR, EHD1, EPN1, FAM125B, FLT1, HLA-A, HLA-B, HLA-C, HSPA2, MET, PDCD6IP,
RAB11B, RAB11FIP3, RAB5C, VTA1
Focal adhesion CAPN2, CAV1, COL4A2, CRK, DOCK1, EGFR, FLT1, FYN, ILK, ITGA5, ITGB1, MET, PIK3R3, PPP1CC, PPP1R12A, PRKCG,
RAC2, THBS1, TLN2, TNXB
Oxidative phosphorylation ATP5D, ATP5I, ATP5J2, ATP5O, COX2, COX5B, CYC1, NDUFA3, NDUFA5, NDUFS6, PPA2, TCIRG1, UQCRB, UQCRC1,
UQCRC2
Parkinson’s disease ATP5D, ATP5O, COX2, COX5B, CYC1, CYCS, NDUFA3, NDUFA5, NDUFS6, SLC25A5, UQCRB, UQCRC1, UQCRC2, VDAC2
Ribosome RPL10A, RPL21, RPL22, RPL31, RPL3, RPL5, RPL9, RPLP1, RPS12, RPS16, RPS19, RPS20, RPS5, RPS6, RPS7, RPS8
Glycolysis/Gluconeogenesis ADH1A, ADH1B, AKR1A1, ALDH1B1, ALDH2, ALDOC, DLD, ENO2, GPI, PGAM2, PGM1, PKM2, TPI1
Viral myocarditis ABL2, CAV1, CYCS, DAG1, FYN, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, MYH15, RAC2
Antigen processing and
presentation
CD74, CTSB, CTSS, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HSPA2, IFI30, PSME2
Cardiac muscle contraction ATP1B3, ATP2A2, COX2, COX5B, CYC1, TPM2, TPM3, UQCRB, UQCRC1, UQCRC2
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Page 5 of 8proteins clustered in each identical pattern reflect differ-
ent molecular networks can maintain the same basic
subcellular function and behavior; meanwhile these dif-
ferences may lead to carcinogenesis. Take the data listed
in Table 2 for instant, the difference between the pro-
teins that belong to same subcellular pattern offer
further evidence that these subcellular patterns deserve
extensively research in BTCC. Meanwhile, our outcome
shows high degree of consistency with previous reports
by that of substantial evidences indicate cytoskeleton,
mitochondrion, and endoplasmic reticulum closely
related with carcinogenesis [18-20].
The presentation of candidate proteins for biomarker
panel discovery is additional contribution of enrich-
ment/depletion analysis. Take the subcellular patterns of
cytoskeleton, mitochondrion, endoplasmic reticulum
that consist of the “hot-spots” in cancer research as
examples. As shown in Figure 2 and Table 2, proteins in
these three subcellular patterns were enriched in both
cancer and normal cells. Though quantitative informa-
tion cannot be obtained, specifically expressed proteins
mean that either the proteins are expressed only in one
tissue, or that significant difference exists in the expres-
sion of protein between the same sample amounts. As
to the concept of GO cellular component enrichment/
depletion analysis, the enriched GO terms indicate the
active function of specific subcellular pattern and the
proteins categorized in these terms were more likely to
be present in biofluid, and more likely to be identified
as biomarkers [21]. Based on the former description, we
can primarily conclude that proteins categorized in
these subcellular patterns might be effective candidates
for the combination of independent, complementary
markers. Most of them are first present in muscle-inva-
sive BTCC research, such as caveolin-1 (CAV1), which
shows tumor specifically expressed categorized to endo-
plasmic reticulum in our practice is a multifunctional
scaffolding protein that regulates multiple cancer-asso-
ciated processes related to malignant tumor progression
[22]. Though most of the proteins listed in Table 2 have
not been previous reported, the roles of these proteins
in muscle-invasive BTCC biology deserve further
investigation.
Proteomics pathway approach is necessary to under-
stand multi-step carcinogenesis and facilitate network-
based multi-target therapy [23,24]. The differentially
expressed proteins mainly located at spliceosome, endo-
cytosis, oxidative phosphorylation, etc. The spliceosome
is a ribonucleoprotein complex involved in RNA spli-
cing, that is, the removal of non-coding introns from
precursor messenger RNA. Splicing events play an
essential role in carcinogenesis and recent researches
discover that the spliceosome is a target for novel com-
pounds with anticancer activity [25]. Derailed endocyto-
sis has emerged in the past 5 years as a multifaceted
hallmark of malignant cells. Although it is unclear to
what extent the endocytic and nuclear functions are
interrelated, several of such proteins are implicated in
the regulation of cell proliferation and carcinogenesis,
arguing that their dual-function nature should be widely
concerned. Pharmaceutical interception of the propen-
sity of tumor cells to derail endocytic signaling and their
adhesion receptors may constitute a novel target for
cancer therapy [26]. Alterations in cellular bioenergetics
contribute to the invasive, metastatic and adaptive prop-
erties typical in most tumors. Glycolytic inhibitors serve
as a classical example of cancer metabolism targeting
agents and several lines of evidence suggest that selec-
tive inhibition of tumor cell OXPHOS may be a rational
approach for the treatment of cancers [27,28]. As pre-
viously described, by cellular pathway analysis, we found
multiple pathway alterations between muscle-invasive
BTCC and normal urothelium. The outcome of pathway
analysis pointed out the direction of biotherapy.
Furthermore, the proteins located in these pathways
offer candidate biomarkers for design network-based
multi-target therapy.
In this study, the largest molecular weight (MW)
values observed in differentially expressed proteins was
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Turning curve shows the global skewness distribution of the data.
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Page 6 of 81153.21 kea, and the proteins were distributed across a
wide isoelectric point (PI) range of 3.67 to 12.14. After
analysis by ArrayTrack, 65 proteins that PI >9a n d6 3
proteins that MW > 100 kDa were defined as potential
biomarkers. Based on these data, shotgun proteomics
not only extenses the coverage of expressed proteome
but also extenses the coverage of the expressed biomar-
kers in muscle-invasive bladder cancer. After categoriz-
ing the data by the detection range of routine 2-DE, the
IQR is 1.97 for PI ≤ 9 and 1.14 for PI > 9, 33.28 for
MW ≤ 100 and 130.84 for MW > 100, respectively.
Further analyses showed that PI ≤ 8a n d8<P I ≤ 10
have normal distribution and the mean ± SD was 5.98 ±
0.86 and 8.94 ± 0.51, respectively. The aim of this pro-
cedure was for the guidance of selective gel excision in
2-DE technology. Though the overall distribution of PI
and MW showed a skewed distribution, the PI distribu-
tion within a specific range shows certain regularity. As
to the definition of normal distribution, all values within
1 SD encompass 68% of the data. Then, in the first
dimension of 2-DE technology, 68% of the potential bio-
markers centered in a range of 5.12 to 6.84 and 8.43 to
9.45 for that of PI ≤ 8 and 8 < PI ≤ 10, respectively.
Conclusions
The present study identified 981 differential proteins
between muscle-invasive BTCC and normal urothelium
by shotgun strategy. GO enrichment/depletion analysis
offer a number of candidate proteins to the combina-
tion of independent, complementary biomarkers and
contribute to selection of specific subcellular pattern
for further study. Pathway analysis reveals the differen-
tially expressed proteins mainly located at spliceosome,
endocytosis, oxidative phosphorylation, etc. Finally,
descriptive statistics find that 68% of the potential bio-
markers centered in a range of 5.12 to 6.84 and 8.43
to 9.45 for that of PI ≤ 8a n d8<P I ≤ 10, respectively.
These findings add our understanding of the mechan-
isms of carcinogenesis and may improve our ability to
discover effective biomarkers for muscle-invasive
BTCC.
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